Therefore, it seems that HSP90 inhibitors would be promising broad-spectrum antiviral drug candidates (21); nevertheless, in contrast to their widespread application in anti-tumor therapies (22), no HSP90 inhibitors are in clinical use for antiviral therapies currently, probably due to unsatisfactory antiviral efficacy and undesirable toxicity. The gene discussed is HSP90AA1; the disease is neoplasm.